Advances in research on neuromyelitis optica spectrum disorders and its clinical heterogeneity  

作　　者：Yi Bao Ming Jin Qi Zhao Lu Liu Yanpeng Sun Xiaoqin Peng Lu Yang Guangjian Liu 

机构地区：[1]Department of Neurology,Taihe Hospital Affiliated to Hubei University of Medicine,Shiyan,Hubei 442000,China

出　　处：《Journal of Translational Neuroscience》2019年第4期13-22,共10页转化神经科学电子杂志（英文）

摘　　要：Neuromyelitis optica spectrum disorders(NMOSD)is a demyelinating disease mainly involving the optic nerve and spinal cord.It has recurrent and aggravating attacks and high disability rate.Most patients have a stepwise progression,resulting in complete blindness or paraplegia.NMOSD lesions contain not only the optic nerve and spinal cord,but also other neurological and non-neurological symptoms,which has clinical heterogeneity.The discovery of aquaporin-4-immunoglobulin G(AQP4-IgG)attributed it to autoimmune ion-channel disease,and rituximab(RTX)has achieved good clinical efficacy in the treatment of NMOSD.Myelin oligodendrocyte glycoprotein(MOG)antibodies have been found in some AQP4-IgG-negative NMOSD patients,which have different clinical and immunological features,posing new challenges to the diagnosis and treatment of NMOSD,which may require re-design and testing of new immune-targeted drugs.

关 键 词：neuromyelitis optica SPECTRUM disorders(NMOSD) aquaporin-4-immunoglobulin G(AQP4-IgG) MYELIN OLIGODENDROCYTE glycoprotein(MOG) rituximab(RTX) PARANEOPLASTIC neurological syndrome 

分 类 号：R73[医药卫生—肿瘤]